Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KIF5B | P33176 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19125882 | 0.89 | KDR (0.43) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL19100410 | 0.86 | ABCG2 (0.46) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL19124188 | 0.85 | KDR (0.48) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL19124213 | 0.83 | KCNH2 (0.55) | EGFRKCNH2ERBB2CYP2D6 | |
| SCHEMBL19100043 | 0.82 | EGFR (0.49) | EGFRKDRERBB2 | |
| SCHEMBL18013058 | 0.81 | EGFR (0.59) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL19100047 | 0.81 | EGFR (0.58) | EGFRKDRERBB2 | |
| SCHEMBL19126094 | 0.78 | KDR (0.52) | EGFRKDRRETKIF5BERBB2 | |
| SCHEMBL19100062 | 0.78 | EGFR (0.53) | EGFRKDRRETKCNH2ERBB2 | |
| SCHEMBL19885271 | 0.78 | KDR (0.54) | EGFRKDRRETKIF5BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| EP-3400216-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | Trillium Therapeutics Inc. (CA) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 202/4885RET 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.